Severe cardiovascular disorders may include severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies disorders caused by the dysfunction of ion channels.
Drugs highly bound to plasma protein: Similarly, atomoxetine did not affect the binding of these compounds to human albumin.
Although some serious structural cardiac abnormalities alone carry an increased risk of sudden death, atomoxetine should only be used with caution in patients with known serious structural cardiac abnormalities and in consultation with a cardiac specialist. Pharmacokinetics of atomoxetine are linear over the range of doses studied in both extensive and poor metabolisers.
Patients requiring long-term therapy should be monitored and consideration should be given to dose reduction or interrupting therapy in children and adolescents who are not growing or gaining weight satisfactorily.
Dysmenorrhoea, ejaculation disorder, erectile dysfunction, prostatitis, male genital pain. Also very rarely, severe liver injury, including acute liver failure, have been reported. Psychotic or manic symptoms: Dysuria, pollakuria, urinary hesitation, urinary retention. Go to top of the page 1. Seizures are a potential risk with atomoxetine. Titanium dioxide E 18 mg: Supply through pharmacy only. Product subject to medical prescription which may be renewed B. Go to top of the page 5.
Therefore, patients requiring long-term therapy should be carefully monitored. Link to this document from your website: Reproductive system and breast disorders.
Asthenia, fatigue, lethargy, chills, feeling jittery, irritability, thirst. However, this study excluded patients who were stimulant nonresponders. Warfarin, acetylsalicylic acid, phenytoin, or diazepam did not affect the binding of atomoxetine to human albumin. Because of its effect on noradrenergic tone, orthostatic hypotension 0. Mechanism of action and Pharmacodynamic effects Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.
Hepatic impairment results in a reduced atomoxetine clearance, increased atomoxetine exposure AUC increased 2-fold in moderate impairment and 4-fold in severe impairmentand a prolonged half-life of parent drug compared to healthy controls with the same CYP2D6 extensive metaboliser genotype.
Clinical efficacy and safety. Blood pressure increased 4heart rate increased 4. Go to top of the page 4. Because of the lack of data, atomoxetine should be avoided during breast-feeding.
- how long will vicodin show on a drug test
- klonopin vs xanax vs ativan vs valium
- what is difference between plavix and coumadin
- alprazolam dose lethal
- cyproheptadine for stomach pain
- side effects of prazosin medication
- what is the generic name for prednisone
- abdominal pain after taking cytotec
- glimepiride tablets 2mg spc